Blocking the Lpd enzyme to fight tuberculosis and related mycobacterial infections
Studies of lipoamide dehydrogenase tight binding inhibition in tuberculous and non-tuberculous mycobacteria
Looking at new compounds that bind a key bacterial enzyme to help create better treatments for tuberculosis and related mycobacterial infections.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11222675 on NIH RePORTER |
What this research studies
This research looks for molecules that stick tightly to a bacterial enzyme called lipoamide dehydrogenase (Lpd) in TB and non-tuberculous mycobacteria. Researchers will use lab enzyme tests and bacterial culture experiments to see which compounds block Lpd and stop bacterial growth. Promising compounds will be studied further in infected cells and in mouse models to check how well they work and whether they are safe. The ultimate goal is to identify drug leads that could move toward clinical testing for people with TB or NTM infections.
Who could benefit from this research
Good fit: People with drug-resistant tuberculosis or persistent non-tuberculous mycobacterial lung infections could be future candidates for therapies developed from this work.
Not a fit: People without TB or NTM infections, or those needing immediate clinical treatment, are unlikely to benefit directly from this preclinical laboratory research right now.
Why it matters
Potential benefit: Could lead to new antibiotics that shorten treatment courses and work against drug-resistant TB and non-tuberculous mycobacterial infections.
How similar studies have performed: Targeting Lpd is a relatively new approach with genetic validation in animal models, but turning Lpd inhibitors into approved drugs remains at an early, largely preclinical stage.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: Bryk, Ruslana — Weill Medical Coll of Cornell Univ
- Study coordinator: Bryk, Ruslana
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.